Edwards Lifesciences Corp
featured
Take a look at some of Tuesdays midday movers.
» Read More
More
-
Among the stock activity stories for Monday, June 10, from AP Business News:. _ Federal-Mogul Corp. shares rose after the auto supplier said it would attempt to refinance $3.05 billion in debt, and forecast better-than-expected revenue for the quarter and the year.
-
NEW YORK-- Shares of Edwards Lifesciences Corp. rose Monday after a Credit Suisse analyst upgraded the stock based on the potential of a new heart valve device. THE SPARK: Analyst Bruce Nudell raised his rating on the stock to "Outperform" from "Neutral" and his price target to $77 from $73.
-
Following upbeat earnings, stocks rally for third straight day. Best 3-day winning streak for S&P 500 since late November, best 3-day winning streak for Nasdaq since early August.
-
April 23- Edwards Lifesciences Corp on Tuesday lowered its 2013 outlook due to sluggish sales at the start of the year for its less-invasive replacement heart valves, and its shares plunged 15 percent after hours.
-
Check out which companies are making headlines after the bell Tuesday:
-
Edwards said that first-quarter net earnings more than doubled, boosted by a large gain from patent litigation with Medtronic Inc. Net income rose to $144.9 million, or $1.24 per share, from $65.1 million, or 55 cents per share, a year ago.
-
April 23- Edwards Lifesciences Corp said on Tuesday first-quarter net earnings more than doubled, boosted by a large gain from patent litigation with Medtronic Inc, but the heart valve maker lowered its 2013 outlook due to sluggish sales at the start of the year. Net income rose to $144.9 million, or $1.24 per share, from $65.1 million, or 55 cents per share, a year ago.
-
SAN FRANCISCO, March 11- Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three years as those who had open-heart surgery, with no increased risk of stroke, according to results from a clinical trial.
-
SAN FRANCISCO, March 11- Patients who received the original version of Edwards Lifesciences Corp's non-invasive heart valve replacement system had a nearly identical death rate after three years as those who had open-heart surgery, with no increased risk of stroke, according to results from a clinical trial.
-
SAN FRANCISCO, March 10- A smaller, redesigned version of Edwards Lifesciences' non-invasive heart valve replacement system called Sapien XT performed well and led to fewer complications than the original Sapien, according to data from a clinical trial presented on Sunday.
-
SAN FRANCISCO, March 10- A smaller, redesigned version of Edwards Lifesciences' non-invasive heart valve replacement system called Sapien XT performed well and led to fewer complications than the original Sapien, according to data from a clinical trial presented on Sunday.
-
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
-
*Q4 profit of 90 cents excluding items tops analysts' 77 cents view. Feb 4- Edwards Lifesciences Corp on Monday posted fourth-quarter earnings that beat analyst expectations on strong sales of its replacement heart valve that is implanted in a less-invasive procedure than open-heart surgery.
-
Check out which companies are making headlines after the bell Monday:
Most Popular Video
The Federal Reserve won't change course on quantitative easing this week, Steve Weiss of Short Hills Capital says.
Tuesday, 18 Jun 2013 | 7:10 AM ETAn airline passenger records a Chinese cargo handler as he tosses boxes of something on to and off of a conveyor belt for shipment. Hopefully, the cargo was packed well.
Tuesday, 18 Jun 2013 | 9:33 AM ETPlans to take PC maker Dell private by leveraging the company's balance sheet are misguided, CNBC's Jim Cramer said on "Squawk on the Street" Tuesday, because the company is facing lower margins and an increased competition from rival Hewlett Packard.